Literature DB >> 2427745

Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting.

G H Cohen, V J Isola, J Kuhns, P W Berman, R J Eisenberg.   

Abstract

Previously, a panel of monoclonal antibodies (MCAb) was used to define specific epitopes of herpes simplex virus glycoprotein D (gD) (R. J. Eisenberg et al., J. Virol. 53:634-644, 1985). Three groups of antibodies recognized continuous epitopes; group VII reacted with residues 11 to 19 of the mature protein (residues 36 to 44 of the predicted sequence), group II reacted with residues 272 to 279, and group V reacted with residues 340 to 356. Four additional antibody groups recognized discontinuous epitopes of gD, since their reactivity was lost when the glycoprotein was denatured by reduction and alkylation. Our goal in this study was to localize more precisely the discontinuous epitopes of gD. Using a nondenaturing system of polyacrylamide gel electrophoresis ("native" gel electrophoresis) coupled to Western blotting, we analyzed the antigenic activity of truncated forms of gD. These fragments were generated either by recombinant DNA methods or by cleavage of purified native gD-1 (gD obtained from herpes simplex virus type 1) and gD-2 (gD obtained from herpes simplex virus type 2) with Staphylococcus aureus protease V8. Antibodies in groups III, IV, and VI recognized three truncated forms of gD-1 produced by recombinant DNA methods, residues 1 to 287, 1 to 275, and 1 to 233. Antibodies in group I recognized the two larger forms but did not react with the gD-1 fragment of residues 1 to 233. On the basis of these and previous results, we concluded that a protion of epitope I was located within residues 233 to 259 and that epitopes III, IV, and VI were upstream of residue 233. Antibodies to continuous epitopes identified protease V8 fragments of gD-1 and gD-2 that contained portions of either the amino or carboxy regions of the proteins. None of the V8 fragments, including a 34K polypeptide containing residues 227 to 369, reacted with group I antibodies. This result indicated that a second portion of epitope I was located upstream of residue 227. Two amino-terminal fragments of gD-1, 33K and 30K, reacted with group III, IV, and VI antibodies. A 33K fragment of gD-2 reacted with group III antibodies. Based on their size and reactivity with endo-beta-N-acetylglycosaminidase F, we hypothesized that the 33K and 30K molecules represented residues 1 to 226 and 1 to 182 of gD-1, respectively. These results suggest that epitopes III, IV, and VI are located within the first 182 residues of gD.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427745      PMCID: PMC253913     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

2.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase.

Authors:  P M Colman; J N Varghese; W G Laver
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

3.  Effect of monoclonal antibodies on limited proteolysis of native glycoprotein gD of herpes simplex virus type 1.

Authors:  R J Eisenberg; D Long; L Pereira; B Hampar; M Zweig; G H Cohen
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

4.  Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4.

Authors:  S D Showalter; M Zweig; B Hampar
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

5.  Purification of glycoprotein gD of herpes simplex virus types 1 and 2 by use of monoclonal antibody.

Authors:  R J Eisenberg; M Ponce de Leon; L Pereira; D Long; G H Cohen
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

6.  Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA.

Authors:  G T Lee; M F Para; P G Spear
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

7.  Application of denatured, electrophoretically separated, and immobilized lysates of herpes simplex virus-infected cells for detection of monoclonal antibodies and for studies of the properties of viral proteins.

Authors:  D K Braun; L Pereira; B Norrild; B Roizman
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

8.  Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli.

Authors:  R J Watson; J H Weis; J S Salstrom; L W Enquist
Journal:  Science       Date:  1982-10-22       Impact factor: 47.728

9.  Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.

Authors:  T C Holland; S D Marlin; M Levine; J Glorioso
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

10.  Visualization of lipoprotein receptors by ligand blotting.

Authors:  T O Daniel; W J Schneider; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

View more
  108 in total

1.  Effects of herpes simplex virus on structure and function of nectin-1/HveC.

Authors:  Claude Krummenacher; Isabelle Baribaud; James F Sanzo; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.

Authors:  S Keay; T C Merigan; L Rasmussen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Striking similarity of murine nectin-1alpha to human nectin-1alpha (HveC) in sequence and activity as a glycoprotein D receptor for alphaherpesvirus entry.

Authors:  D Shukla; M C Dal Canto; C L Rowe; P G Spear
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; Don C Wiley; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Potential nectin-1 binding site on herpes simplex virus glycoprotein d.

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; J Charles Whitbeck; Yi Zuo; Don C Wiley; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry.

Authors:  Claude Krummenacher; Vinit M Supekar; J Charles Whitbeck; Eric Lazear; Sarah A Connolly; Roselyn J Eisenberg; Gary H Cohen; Don C Wiley; Andrea Carfí
Journal:  EMBO J       Date:  2005-11-17       Impact factor: 11.598

7.  Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.

Authors:  Florent C Bender; J Charles Whitbeck; Huan Lou; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G.

Authors:  I Frank; H M Friedman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

9.  Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D.

Authors:  D L Sodora; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Expression of bovine herpesvirus 1 glycoprotein gIV by recombinant baculovirus and analysis of its immunogenic properties.

Authors:  S van Drunen Littel-van den Hurk; M D Parker; D R Fitzpatrick; T J Zamb; J V van den Hurk; M Campos; R Harland; L A Babiuk
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.